Cerus预计2025年收入将增长14%，指导2026年

2026-01-12 15:35

Cerus (CERS) announced preliminary unaudited product revenue results for Q4 and FY, showing strong growth in its blood safety products, particularly the INTERCEPT Fibrinogen Complex (IFC)
Q4 product revenue is expected to touch $57.8M, up 14% Y/Y. IFC contributed $4.2M in this period, reflecting about 40% Y/Y growth.
FY product revenue is expected to be $206.1M, 14% growth vs. prior year. IFC accounted for $16.7M, roughly 80% growth Y/Y.
The company expects FY 2026 product revenue to be in the range of $224M to $228M, representing Y/Y growth of 9%-11% compared to preliminary unaudited 2025 product revenue. Included in the 2026 guidance range is expected full-year 2026 IFC revenue of $20 million to $22 million, representing year-over-year growth of approximately 20% to 30% from 2025.
The stock price rose ~2% on Monday during pre-market hours of trading.

More on Cerus